Corps Capital Advisors LLC Cuts Holdings in AbbVie Inc. $ABBV

Corps Capital Advisors LLC trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 52.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,342 shares of the company’s stock after selling 4,803 shares during the period. AbbVie comprises 1.3% of Corps Capital Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. Corps Capital Advisors LLC’s holdings in AbbVie were worth $806,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. TD Capital Management LLC raised its stake in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the 2nd quarter worth approximately $25,000. Abound Financial LLC purchased a new position in shares of AbbVie during the 1st quarter worth approximately $30,000. Cypress Capital Management LLC WY purchased a new position in AbbVie in the 1st quarter valued at approximately $35,000. Finally, Bear Mountain Capital Inc. increased its stake in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.25% of the stock is owned by company insiders.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $216.09 on Wednesday. The business’s fifty day moving average price is $222.66 and its two-hundred day moving average price is $201.73. The stock has a market cap of $381.73 billion, a PE ratio of 102.90, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Piper Sandler raised their price objective on AbbVie from $231.00 to $284.00 and gave the company an “overweight” rating in a research note on Friday, October 10th. Evercore ISI raised their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Finally, Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $237.81.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.